Dermapharm Holding SE, alongside its group companies, specializes in the off-patent branded pharmaceutical market, serving both German and international clients. The company’s operations are organized into three primary divisions: Branded Pharmaceuticals and Other Healthcare Products, Parallel Import Business, and Herbal Extracts. It undertakes the development, manufacturing, licensing, marketing, and sale of branded generic medicines, over-the-counter remedies, non-prescription natural health solutions, and various other healthcare items. Dermapharm's product range covers areas such as vitamins, minerals, nutritional supplements, dermatology, allergology, pain and inflammation management, cardiovascular support, gynecology, and urology, prominently featuring brands like Dekristol, Dekristolvit, Allergovit, and Tromcardin. Additionally, the company provides medical devices including bite away and Herpotherm, as well as specific pharmaceutical preparations like Momekort, a nasal spray for allergy symptoms, and Azedil, which functions as a nasal spray or eye drop. It also manages the importation of originator pharmaceuticals under the axicorp brand. Furthermore, Dermapharm supplies herbal extracts and natural active ingredients for application in phytopharmaceuticals, nutraceuticals, and cosmetics. Its clientele encompasses pharmaceutical wholesalers, retail pharmacies, hospitals, and health food stores. Founded in 1991 and headquartered in Grünwald, Germany, Dermapharm Holding SE is a subsidiary of Themis Beteiligungs-Aktiengesellschaft.
The current price of DMPHF is $47.69 USD — it has increased by +0% in the past 24 hours. Watch Dermapharm stock price performance more closely on the chart.
What is Dermapharm stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on OTC Link exchange Dermapharm stocks are traded under the ticker DMPHF.
When is the next Dermapharm earnings date?▼
Dermapharm is going to release the next earnings report on November 12, 2026.
What were Dermapharm earnings last quarter?▼
DMPHF earnings for the last quarter are 0.54 USD per share, whereas the estimation was N/A USD resulting in a N/A surprise. The estimated earnings for the next quarter are N/A USD per share.
What is Dermapharm revenue for the last year?▼
Dermapharm revenue for the last year amounts to 1.34B USD.
What is Dermapharm net income for the last year?▼
DMPHF net income for the last year is 152.44M USD.
Does Dermapharm pay dividends?▼
Yes, DMPHF dividends are paid annual. The last dividend per share was 1 . As of today, Dividend Yield (FWD)% is 2.1%.
How many employees does Dermapharm have?▼
As of November 11, 2026, the company has 3,619 employees.
In which sector is Dermapharm located?▼
Dermapharm operates in the Health & Wellness sector.